Company Overview and News
Investors are always on the lookout for a winning strategy, which is easier said than done. When markets are rattled by widespread global growth concerns, it is difficult for even the most perceptive investors to come up with a foolproof plan. No matter how disciplined and systematic investors are, equity market volatility will always manage to get the better of them. While a few lucky ones rake in the moolah, others fall victim to ad hoc strategies.
HSC MNESP TPB MSA WTW ENVA JOUT
We issued an updated research report on Fortune Brands Home & Security, Inc. (FBHS - Free Report) on Jun 12. This security and safety service provider currently carries a Zacks Rank #3 (Hold). Its market capitalization is approximately $8.4 billion. Let’s delve deeper and discuss the company’s potential growth drivers and possible headwinds. Factors Aiding Fortune Brands Favorable Operating Conditions: We believe that security and safety service provider companies are poised to benefit from the strengthening of U.
MNESP FBHS MSA JCI AAXN
Chicago, IL – June 8, 2018 - Stocks in this week’s article include: Delta Apparel, Inc. (DLA - Free Report) , Turtle Beach Corp. (HEAR - Free Report) , MSA Safety Inc. (MSA - Free Report) and QuinStreet, Inc. (QNST - Free Report) .
TTWO FIX MSA LB QNST UFPI BKNG MNESP MU PATK HEAR DLA PETS
If achieving profit is a company’s goal then having a healthy cash flow is most essential to its existence, development and success. Cash offers the flexibility to make decisions, the means to make investments, the fuel to run its growth engine and can indeed be called the lifeblood of any business.
MNESP HEAR MSA DLA QNST
If achieving profit is a company’s goal then having a healthy cash flow is most essential to its existence, development and success. Cash offers the flexibility to make decisions, the means to make investments, the fuel to run its growth engine and can indeed be called the lifeblood of any business. Often investors flock to companies that earn profits. But even a profit-making company can have a dearth of cash flow and face bankruptcy while meeting its obligations.
MNESP MSA HEAR DLA QNST
Industrial production increased in April, marking the third consecutive month of gains. Gains were broad-based with advances coming from mining, utilities and factories. However, the increase in manufacturing output was notable. This is because factory-based production had remained flat in the preceding month.
CATR MNESP GGG CAT TWI MSA
Chicago, IL – May 23, 2018 - Stocks in this week’s article Ternium S.A. (TX - Free Report) , MSA Safety Inc. (MSA - Free Report) , Century Communities, Inc. (CCS - Free Report) , Expeditors International of Washington, Inc. (EXPD - Free Report) and Bryn Mawr Bank Corporation (BMTC - Free Report) .
CCS STT TPOYY KBH DB STT.PRC STT.PRE STT.PRD STT.PRG MSA TAPOF EXPD X MNESP KHC BMTC TAP
Driehaus strategy is an investment approach developed by Richard Herman Driehaus using the "buy high and sell higher" principle. This strategy can be used by investors with high-risk appetite by investing mainly in momentum stocks. The success of this investment approach helped Driehaus secure a name in Barron’s All-Century Team.
CCS EXPD HAFC MNESP MSA BMTC AAP AKAM
Axon Enterprise, Inc. (AAXN - Free Report) was a big mover last session, as the company saw its shares rise more than 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up 32.9% in the past one-month time frame.
AWI MNESP MSA AAXN
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
2018-06-11 - Asif
Overview Stemline Therapeutics was incorporated under the laws of the State of Delaware in August 2003. Stemline Therapeutics is a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and potentially commercializing innovative oncology therapeutics that target difficult to treat cancers. The company's clinical pipeline includes: SL-401, SL-801, and SL-701. SL-401 pivotal data; plans for registration and potential commercialization: SL-401 has completed a pivotal trial in patients with blastic plasmacytoid dendritic cell neoplasm, or BPDCN, and has successfully met the primary endpoint of the trial. SL-401 is a targeted therapy directed to the interleukin-3 receptor-a, or CD123. SL-401 was granted breakthrough therapy designation, or BTD, by the U.S. Food and Drug Administration, or FDA, for the treatment of patients with BPDCN. Based on the trial results and other data, the company expect to complete submission of a rolling Biologics License...
Silicon Investor Message Boards
This table lists all message boards related to MSA / MSA Safety Inc. on message board site Silicon Investor.
|MSA: Mine Safety Appliances||COMSAT|
|Emsanet, a no frills online provider||INTIME SYSTEMS INTERNATIONAL(TAMSA)|
as of ET